Although many patients have an underlying cancer, the prognosis is determined by the severity of the neurological symptoms produced by the<unk> . Compared to other paraneoplastic<unk> es,<unk>  has an especially poor prognosis. Several studies reporting an average survival time of less than a year, from the time of diagnosis. Much of the prognosis depends on the efficacy of treatment, which is directed at the underlying cancer, if present. Patients with lower titers of the<unk> -Hu<unk> body tend to have a better prognosis.
Anti-Hu associated encephalitis
Anti-NMDA receptor encephalitis
Anti-VGKC-complex encephalitis
Powassan encephalitis
Post viral cerebellar ataxia
Anti-neurofascin demyelinating diseases
Viliuisk encephalomyelitis
Limbic-predominant age-related TDP-43 encephalopathy